<DOC>
	<DOCNO>NCT01486849</DOCNO>
	<brief_summary>A Phase II , double-blind , randomize , placebo-controlled ascend dose titration study evaluate safety , tolerability , pharmacokinetics pharmacodynamic effect multiple ascend dos CK-2017357 individual patient maximum tolerate dose ( MTD ) , use within-patient twice daily ( BID ) dose-titration regimen ALS patient 50 mg riluzole daily ( QD ) .</brief_summary>
	<brief_title>Dose Titration Study Test Safety Effects CK-2017357 Patients With Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description>Patients randomize one two dose group , active CK-2017357 placebo , 3:1 ratio . Prior study drug dosing , patient require decrease riluzole dose 50 mg QD 7 day ; 7 day period patient either receive placebo start titration active CK-2017357 continue take riluzole 50 mg QD . Potential patient screen assess eligibility enter study within 21 day prior Day -7 , begin take riluzole decrease dose 50 mg QD . Patients randomize 3:1 ratio CK-2017357 ( Group 1 ) placebo ( Group 2 ) . On Day 1 , patient begin take total daily dose 250 mg ( 125 mg BID ) CK-2017357 match placebo tablet BID 7 day . Then take total daily dose 375 mg ( 125 mg morning [ AM ] 250 mg even [ PM ] ) CK-2017357 match placebo tablet BID 7 day , finally , take total daily dose 500 mg ( 250 mg BID ) CK-2017357 match placebo tablet BID 7 day . A final dose 250 mg CK-2017357 placebo take morning Day 22 study site . Dose-escalation CK-2017357 placebo may stop , dose reduce low level , base tolerability . All patient return low dose stay dose remainder study . Patients remain decreased dose riluzole follow-up visit approximately 7 day Day 22 .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>1 . Able comprehend willing sign Informed Consent Form ( ICF ) 2 . Males females 18 year age old 3 . A diagnosis familial sporadic ALS ( define meeting possible , laboratorysupported probable , probable , definite criterion diagnosis ALS accord World Federation Neurology El Escorial criterion ) 4 . Maximum voluntary grip strength least one hand 10 &amp; 40 pound ( female ) 10 &amp; 60 pound ( male ) 5 . Able swallow tablet water 6 . Currently take tolerate stable dose 50 mg BID riluzole 7 . Willing able reduce daily dose riluzole 50mg QD 5 week 8 . Not currently take willing able remain theophyllinecontaining medication study participation 9 . Patient caregiver capable observe report patient status 10 . Upright Slow Vital Capacity ( SVC ) &gt; 50 % predicted age , height , sex 11 . Able perform pulmonary function test 1 . Life expectancy &lt; 3 month 2 . Receipt investigational study drug within 30 day 5 halflives prior agent , whichever great , prior dose 3 . Any prior treatment CK2017357 4 . Any use noninvasive positive pressure ventilation ( NIPPV ) , Continuous Positive Airway Pressure ( CPAP ) Bilevel Positive Airway Pressure ( BiPAP ) Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>